Business Description
Egetis Therapeutics AB
NAICS : 325412
SIC : 2834
ISIN : SE0003815604
Compare
Compare
Traded in other countries / regions
EGTX.Sweden0ABW.UKP0F.Germany IPO Date
2011-04-07Description
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.77 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.39 | |||||
| Beneish M-Score | -0.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.3 | |||||
| 3-Year EBITDA Growth Rate | 20.2 | |||||
| 3-Year EPS without NRI Growth Rate | 18.5 | |||||
| 3-Year FCF Growth Rate | 16.4 | |||||
| 3-Year Book Growth Rate | -19 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 141.56 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 89.47 | |||||
| 9-Day RSI | 78.58 | |||||
| 14-Day RSI | 69.3 | |||||
| 6-1 Month Momentum % | -26.32 | |||||
| 12-1 Month Momentum % | -9.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.56 | |||||
| Quick Ratio | 1.55 | |||||
| Cash Ratio | 1.29 | |||||
| Days Inventory | 1.62 | |||||
| Days Sales Outstanding | 102.9 | |||||
| Days Payable | 68.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.6 | |||||
| Shareholder Yield % | -5.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -65.4 | |||||
| Operating Margin % | -436.44 | |||||
| Net Margin % | -450.99 | |||||
| FCF Margin % | -348.31 | |||||
| ROE % | -65.49 | |||||
| ROA % | -49.13 | |||||
| ROIC % | -63.25 | |||||
| 3-Year ROIIC % | -807.96 | |||||
| ROC (Joel Greenblatt) % | -6816.96 | |||||
| ROCE % | -55.11 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 39.24 | |||||
| PS Ratio | 21.77 | |||||
| PB Ratio | 3.94 | |||||
| EV-to-EBIT | -6.08 | |||||
| EV-to-Forward-EBIT | 5.77 | |||||
| EV-to-EBITDA | -6.11 | |||||
| EV-to-Forward-EBITDA | 5.77 | |||||
| EV-to-Revenue | 26.22 | |||||
| EV-to-Forward-Revenue | 2.52 | |||||
| EV-to-FCF | -7.53 | |||||
| Earnings Yield (Greenblatt) % | -16.45 | |||||
| FCF Yield % | -12.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Egetis Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 70.8 | ||
| EPS (TTM) (kr) | -1.1 | ||
| Beta | 0.13 | ||
| Volatility % | 64.57 | ||
| 14-Day RSI | 69.3 | ||
| 14-Day ATR (kr) | 0.323261 | ||
| 20-Day SMA (kr) | 4.56425 | ||
| 12-1 Month Momentum % | -9.59 | ||
| 52-Week Range (kr) | 4.04 - 9.3 | ||
| Shares Outstanding (Mil) | 359.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Egetis Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Egetis Therapeutics AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Egetis Therapeutics AB Frequently Asked Questions
What is Egetis Therapeutics AB(OSTO:EGTX)'s stock price today?
The current price of OSTO:EGTX is kr5.40. The 52 week high of OSTO:EGTX is kr9.30 and 52 week low is kr4.04.
When is next earnings date of Egetis Therapeutics AB(OSTO:EGTX)?
The next earnings date of Egetis Therapeutics AB(OSTO:EGTX) is 2025-02-21 Est..
Does Egetis Therapeutics AB(OSTO:EGTX) pay dividends? If so, how much?
Egetis Therapeutics AB(OSTO:EGTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers